Prospective Clinical Genomic Profiling of Ewing Sarcoma: <i>ERF</i> and <i>FGFR1</i> Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic Relevance.

Ogura, Koichi; Elkrief, Arielle; Bowman, Anita S; Koche, Richard P; de Stanchina, Elisa; Benayed, Ryma; Mauguen, Audrey; Mattar, Marissa S; Khodos, Inna; Meyers, Paul A; Healey, John H; Tap, William D; Hameed, Meera; Zehir, Ahmet; Shukla, Neerav; Sawyers, Charles; Bose, Rohit; Slotkin, Emily; Ladanyi, Marc

Prospective Clinical Genomic Profiling of Ewing Sarcoma: ERF and FGFR1 Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic Relevance.

Ogura, Koichi; Elkrief, Arielle; Bowman, Anita S; Koche, Richard P; de Stanchina, Elisa; Benayed, Ryma; Mauguen, Audrey; Mattar, Marissa S; Khodos, Inna; Meyers, Paul A; Healey, John H; Tap, William D; Hameed, Meera; Zehir, Ahmet; Shukla, Neerav; Sawyers, Charles; Bose, Rohit; Slotkin, Emily; Ladanyi, Marc.

Afiliação

Ogura K; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
Elkrief A; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Bowman AS; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
Koche RP; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
de Stanchina E; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
Benayed R; Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY.
Mauguen A; Anti-tumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Mattar MS; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
Khodos I; AstraZeneca Pharmaceuticals, Wilmington, DE.
Meyers PA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
Healey JH; Anti-tumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Tap WD; Anti-tumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Hameed M; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.
Zehir A; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.
Shukla N; Department of Surgery, Orthopaedic Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Sawyers C; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.
Bose R; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
Slotkin E; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
Ladanyi M; AstraZeneca Pharmaceuticals, Wilmington, DE.

JCO Precis Oncol ; 6: e2200048, 2022 08.

Article em En | MEDLINE | ID: mdl-35952322

Assuntos

Produtos Biológicos; Tumores Neuroectodérmicos Primitivos Periféricos; Sarcoma de Ewing; Adulto; Produtos Biológicos/uso terapêutico; Genômica; Humanos; Mutação/genética; Estudos Prospectivos; Receptor Tipo 1 de Fator de Crescimento de Fibroblastos/genética; Proteínas Repressoras/genética; Sarcoma de Ewing/genética; Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sarcoma de Ewing / Produtos Biológicos / Tumores Neuroectodérmicos Primitivos Periféricos País/Região como assunto: America do norte Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google